What is the dosage of albendazole in ascariasis?
Which drug has an anti-androgenic effect?
What is the mechanism of action of vancomycin?
What is the drug of choice for treating infections caused by extended-spectrum beta-lactamase (ESBL) producing organisms?
Linezolid is best used for which of the following organisms?
Which of the following drugs used in the treatment of tuberculosis (ATT) are bactericidal?
Which of the following statements about cefuroxime is true?
Discoloration of the skin, mucosa, and nails is a side effect of which medication?
All of the following are used in the treatment of HIV infection, EXCEPT:
What is the drug of choice for the following worm infection?

Explanation: **Explanation:** **Albendazole** is a broad-spectrum benzimidazole anthelmintic that acts by inhibiting microtubule synthesis (binding to β-tubulin) and glucose uptake in nematodes, leading to their immobilization and death. **Why Option A is correct:** For **Ascariasis** (*Ascaris lumbricoides* or roundworm), a **single dose of 400 mg** of Albendazole is the standard treatment for adults and children over 2 years of age. Because *Ascaris* resides in the lumen of the small intestine and is highly sensitive to the drug, a single oral dose achieves sufficient intraluminal concentration to paralyze and expel the worms. **Why the other options are incorrect:** * **Option B & C:** These are not standard regimens for common intestinal nematodes. Increasing the frequency to twice or thrice daily for a single day does not significantly improve the cure rate for Ascariasis but increases the risk of gastrointestinal side effects. * **Option D:** A multi-day regimen (400 mg twice daily for 3–7 days) is typically reserved for systemic or tissue-invasive infections, such as **Hydatid disease** (*Echinococcus granulosus*) or **Neurocysticercosis** (*Taenia solium* larvae), where prolonged systemic absorption is required. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Inhibition of microtubule polymerization by binding to β-tubulin. * **Spectrum:** Effective against Roundworm, Hookworm, Whipworm, and Pinworm (Enterobiasis). * **Enterobiasis (Pinworm):** Requires 400 mg once, **repeated after 2 weeks** to prevent reinfection from hatched eggs. * **Strongyloidiasis:** Requires 400 mg daily for **3 days**. * **Contraindication:** Albendazole is **embryotoxic** and should be avoided during the first trimester of pregnancy. * **Administration:** For systemic infections (Hydatid/Cysticercosis), it should be taken with a **fatty meal** to enhance absorption.
Explanation: **Explanation:** **Ketoconazole** is the correct answer because it is a non-selective inhibitor of cytochrome P450 enzymes. While its primary antifungal mechanism is the inhibition of 14-$\alpha$-demethylase (converting lanosterol to ergosterol), it also significantly inhibits human steroid synthesis enzymes, specifically **17,20-lyase** and **side-chain cleavage enzyme**. This leads to a decrease in the production of testosterone and cortisol, resulting in clinical **anti-androgenic effects** such as gynecomastia, loss of libido, and impotence in males. **Analysis of Incorrect Options:** * **Amphotericin B (A):** A polyene antifungal that binds to ergosterol in the fungal cell membrane to create pores. It does not interfere with steroidogenesis; its primary dose-limiting toxicity is nephrotoxicity. * **Voriconazole (C) and Posaconazole (D):** These are second-generation triazoles. Unlike the older imidazole (Ketoconazole), triazoles are much more selective for fungal CYP450 enzymes and have a negligible effect on human steroid synthesis. Therefore, they do not cause anti-androgenic side effects. **High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Use of Side Effect:** Due to its ability to inhibit steroid synthesis, Ketoconazole is used therapeutically in the management of **Cushing’s Syndrome** and advanced **Prostate Cancer**. * **Drug Interactions:** Ketoconazole is a potent **CYP3A4 inhibitor**, leading to numerous drug-drug interactions (e.g., increasing levels of statins or warfarin). * **Absorption:** It requires an **acidic gastric pH** for absorption; therefore, its efficacy is reduced when co-administered with PPIs or H2 blockers.
Explanation: **Explanation:** **1. Why Option A is Correct:** Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis. Its mechanism is distinct from beta-lactams: it binds directly to the **D-alanyl-D-alanine** terminus of the nascent peptidoglycan pentapeptide. This binding creates a "steric hindrance" that prevents the transglycosylation and transpeptidation steps, effectively halting the cross-linking of the peptidoglycan layer. This leads to cell lysis. Because it does not bind to Penicillin-Binding Proteins (PBPs), it remains effective against MRSA. **2. Why Other Options are Incorrect:** * **Option B (Protein Synthesis):** This is the mechanism for Aminoglycosides, Tetracyclines, Macrolides, and Chloramphenicol (targeting 30S or 50S ribosomal subunits). * **Option C (Membrane Permeability):** This describes the action of Daptomycin or Polymyxins (like Colistin), which disrupt the integrity of the bacterial cell membrane. * **Option D (Folic Acid Metabolism):** This is the mechanism for Sulfonamides (inhibit dihydropteroate synthase) and Trimethoprim (inhibit dihydrofolate reductase). **3. NEET-PG High-Yield Clinical Pearls:** * **Spectrum:** Exclusively Gram-positive (too large to pass through Gram-negative porins). * **Drug of Choice (DOC):** MRSA (Methicillin-resistant *Staphylococcus aureus*) and *Clostridium difficile* (given **orally** for pseudomembranous colitis). * **Adverse Effects:** * **Red Man Syndrome:** Due to rapid IV infusion causing histamine release (prevented by slow infusion/antihistamines). * **Ototoxicity and Nephrotoxicity:** Risk increases when co-administered with aminoglycosides. * **Resistance:** Occurs via a change in the binding site from D-Ala-D-Ala to **D-Ala-D-Lactate** (seen in VRSA/VRE).
Explanation: ### Explanation **1. Why Imipenem is the Correct Answer:** Extended-spectrum beta-lactamases (ESBLs) are enzymes produced by certain Gram-negative bacteria (most commonly *E. coli* and *Klebsiella*) that mediate resistance to almost all beta-lactam antibiotics, including third and fourth-generation cephalosporins and monobactams. **Carbapenems (such as Imipenem, Meropenem, and Ertapenem)** are the drugs of choice for ESBL-producing organisms because they are highly stable against hydrolysis by these specific enzymes. They remain the "gold standard" for serious infections caused by ESBL-producing Enterobacteriaceae. **2. Why the Other Options are Incorrect:** * **A. Aztreonam:** This is a monobactam. ESBL enzymes effectively hydrolyze monobactams, making them ineffective against ESBL-producing strains. * **C. Cefepime:** This is a 4th-generation cephalosporin. While it shows some stability against other beta-lactamases, it is generally degraded by ESBLs and is associated with high failure rates in clinical practice for these infections. * **D. Ceftazidime:** This is a 3rd-generation cephalosporin. ESBLs were specifically named for their ability to extend their spectrum of resistance to include these drugs. **3. High-Yield Clinical Pearls for NEET-PG:** * **Marker for ESBL:** Resistance to Ceftazidime or Cefotaxime in *E. coli* or *Klebsiella* is a common laboratory marker for ESBL production. * **Carbapenemase:** If an organism becomes resistant to Imipenem, it likely produces **Carbapenemase** (e.g., NDM-1). The drug of choice then shifts to **Colistin, Polymyxin B, or Tigecycline**. * **Cilastatin:** Imipenem is always co-administered with Cilastatin (a dehydropeptidase-I inhibitor) to prevent its degradation in the renal tubules and avoid nephrotoxicity.
Explanation: ### Explanation **Correct Answer: B. VRSA (Vancomycin-resistant Staphylococcus aureus)** **Why it is correct:** Linezolid is a synthetic oxazolidinone antibiotic that inhibits protein synthesis by binding to the **23S ribosomal RNA of the 50S subunit**, preventing the formation of the 70S initiation complex. Its primary clinical utility lies in its activity against "difficult-to-treat" Gram-positive cocci. While it is effective against MRSA, its **"best" or most critical use** in a clinical and examination context is for **VRSA** and **VRE (Vancomycin-resistant Enterococci)**, where traditional glycopeptides like Vancomycin fail. It serves as a reserve drug to prevent the development of further resistance. **Why the other options are incorrect:** * **A. MRSA:** While Linezolid is highly effective against MRSA, it is often considered a second-line or alternative treatment to Vancomycin (which remains the standard of care). In MCQ patterns, when both MRSA and VRSA are present, VRSA is the superior answer as it represents the specific niche where Linezolid is indispensable. * **C & D. K. pneumoniae and E. coli:** These are Gram-negative organisms. Linezolid has **no significant activity against Gram-negative bacteria** because its target site is different and it is often effluxed out of these cells. **NEET-PG High-Yield Pearls:** * **Mechanism:** Unique inhibition of the **70S initiation complex** (no cross-resistance with other protein synthesis inhibitors). * **Spectrum:** Exclusively **Gram-positive** (MRSA, VRSA, VRE, and *S. pneumoniae*). * **Side Effects:** 1. **Bone marrow suppression:** Specifically **thrombocytopenia** (usually after 2 weeks of therapy). 2. **Mitochondrial toxicity:** Can lead to peripheral neuropathy and optic neuritis. 3. **Serotonin Syndrome:** Linezolid is a weak non-selective **MAO inhibitor**; avoid co-administration with SSRIs. * **Pharmacokinetics:** 100% oral bioavailability (IV to Oral switch is 1:1).
Explanation: In the treatment of Tuberculosis (ATT), drugs are classified based on their ability to either kill the bacilli (**Bactericidal**) or merely inhibit their growth (**Bacteriostatic**). ### **Why Pyrazinamide is Correct** **Pyrazinamide (PZA)** is a potent **bactericidal** drug, specifically effective against intracellular Mycobacteria residing within acidic environments (like macrophages). It is converted into pyrazinoic acid by the enzyme *pyrazinamidase*, which disrupts bacterial cell membrane metabolism and transport. Its unique ability to kill "slowly multiplying" persistent bacilli makes it essential for shortening the duration of therapy from 9 months to 6 months. ### **Why the Other Options are Incorrect** * **Ethambutol (B):** This is the only primary (first-line) ATT drug that is **bacteriostatic**. It works by inhibiting *arabinosyl transferase*, preventing cell wall synthesis. It is used primarily to prevent the emergence of resistance to other drugs. * **PAS (C) and Thiacetazone (D):** These are second-line drugs and are strictly **bacteriostatic**. PAS inhibits folic acid synthesis, while Thiacetazone inhibits mycolic acid synthesis, but neither possesses the potency to actively kill the bacilli. ### **High-Yield Clinical Pearls for NEET-PG** * **Mnemonic for Bactericidal ATT:** "**RIP**" (**R**ifampicin, **I**soniazid, **P**yrazinamide). Streptomycin is also bactericidal. * **Mnemonic for Bacteriostatic ATT:** "**E**very **T**ime **P**ause" (**E**thambutol, **T**hiacetazone, **P**AS). * **Pyrazinamide Side Effects:** Most common is **Hyperuricemia** (leading to Gout) and it is the most **hepatotoxic** first-line drug (though Rifampicin is the most common cause of jaundice). * **Ethambutol Side Effect:** **Optic neuritis** (red-green color blindness); it is contraindicated in children who cannot undergo visual testing.
Explanation: **Explanation:** **Cefuroxime** is a second-generation cephalosporin known for its stability against beta-lactamases produced by *H. influenzae* and *M. catarrhalis* [3]. **Why Option D is Correct:** Like most cephalosporins, cefuroxime is primarily eliminated unchanged by the kidneys via **tubular secretion and glomerular filtration** [1]. It has a relatively short half-life (approx. 1.7 hours), necessitating frequent dosing unless administered in its prodrug form (Cefuroxime axetil). Probenecid can delay its excretion by competing for tubular secretion [1]. **Analysis of Incorrect Options:** * **Option A:** Cefuroxime lacks significant activity against anaerobes like *Bacteroides fragilis* [3]. For anaerobic coverage, second-generation cephamycins (Cefoxitin or Cefotetan) are preferred. * **Option B & C:** Although cefuroxime can reach therapeutic levels in the CSF when meninges are inflamed, its penetration is **inconsistent and inferior** compared to third-generation cephalosporins. Furthermore, it has been associated with delayed CSF sterilization and a higher incidence of hearing loss in pediatric meningitis. Therefore, **Ceftriaxone or Cefotaxime** remain the gold standard for meningitis. **High-Yield NEET-PG Pearls:** 1. **Cefuroxime Axetil:** The oral prodrug form of cefuroxime; its absorption is significantly **enhanced when taken with food** [2]. 2. **Surgical Prophylaxis:** Cefuroxime is frequently used for community-acquired pneumonia and certain surgical prophylaxis (though Cefazolin is more common for the latter). 3. **Spectrum:** It bridges the gap between 1st and 3rd generations, offering better Gram-negative coverage (*H. influenzae*) than 1st gen, but less than 3rd gen [3].
Explanation: **Explanation:** **Zidovudine (AZT)**, a Nucleoside Reverse Transcriptase Inhibitor (NRTI), is classically associated with **hyperpigmentation** of the nails (melanonychia), skin, and oral mucosa. This occurs due to the stimulation of melanocytes by the drug or its metabolites, leading to increased melanin deposition. **Analysis of Options:** * **Zidovudine (Correct):** Beyond pigmentation, its dose-limiting toxicity is **bone marrow suppression**, specifically macrocytic anemia and neutropenia. It is also used for the prevention of mother-to-child transmission (MTCT) of HIV. * **Lamivudine (Incorrect):** This is one of the safest NRTIs. Its primary side effects are minimal (headache, nausea) and it is also used in the treatment of Hepatitis B. * **Stavudine (Incorrect):** It is notorious for causing **mitochondrial toxicity**, leading to peripheral neuropathy, lipodystrophy (fat redistribution), and potentially fatal lactic acidosis. * **Enfuvirtide (Incorrect):** This is a Fusion Inhibitor administered subcutaneously. Its most common side effect is **injection site reactions** (nodules, erythema). **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Zidovudine:** **Z**idovudine causes **Z**ero blood cells (Anemia) and **Z**ebra nails (Pigmentation). * **Lopinavir/Ritonavir:** Associated with metabolic complications like dyslipidemia and hyperglycemia. * **Abacavir:** Associated with life-threatening hypersensitivity reactions (linked to **HLA-B*5701**). * **Nevirapine:** Known for causing severe hepatotoxicity and Stevens-Johnson Syndrome (SJS). * **Indinavir:** Associated with nephrolithiasis (crystalluria).
Explanation: The correct answer is **Tegaserod**. **1. Why Tegaserod is the correct answer:** Tegaserod is not an antiretroviral agent. It is a **5-HT₄ receptor partial agonist** used in the treatment of Irritable Bowel Syndrome with constipation (IBS-C) and chronic idiopathic constipation. It works by stimulating the peristaltic reflex and intestinal secretion. It has no activity against the Human Immunodeficiency Virus (HIV). **2. Analysis of incorrect options (Antiretrovirals):** * **Elvucitabine (Option A):** This is an experimental **Nucleoside Reverse Transcriptase Inhibitor (NRTI)**. It is an L-cytosine nucleoside analog that has shown potent activity against both HIV and Hepatitis B Virus (HBV). * **Bevirimat (Option B):** This represents a novel class of anti-HIV drugs called **Maturation Inhibitors**. It works by inhibiting the cleavage of the Gag precursor protein, resulting in the production of immature, non-infectious virus particles. * **Maraviroc (Option C):** This is a **CCR5 Antagonist** (Entry Inhibitor). It binds to the CCR5 receptor on the surface of T-cells, preventing the HIV gp120 protein from docking and entering the host cell [2]. It is only effective against R5-tropic virus [1]. **Clinical Pearls for NEET-PG:** * **Maraviroc** requires a "Tropism Assay" (Trofile test) before initiation to ensure the patient has the R5-tropic strain. * **Enfuvirtide** is another entry inhibitor, but it acts as a **Fusion Inhibitor** by binding to gp41 [1]. * **Integrase Inhibitors (INSTIs)** like Dolutegravir are currently preferred first-line agents in ART regimens due to high efficacy and a high genetic barrier to resistance.
Explanation: ***Albendazole*** - **Broad-spectrum benzimidazole** anthelmintic that is highly effective against **intestinal nematodes** including *Ascaris lumbricoides*. - Has **superior tissue penetration** and **longer half-life** compared to mebendazole, making it the preferred choice for systemic infections. *Mebendazole* - Also a **benzimidazole anthelmintic** effective against intestinal worms but has **poor systemic absorption**. - Less effective for **tissue-migrating larvae** and **extraintestinal infections** compared to albendazole. *Ivermectin* - Primarily effective against **filarial worms** and **ectoparasites** like *Strongyloides* and *Onchocerca*. - **Not the first-line treatment** for common intestinal nematodes like *Ascaris lumbricoides*. *Diethylcarbamazine* - Specifically used for **filarial infections** caused by *Wuchereria bancrofti*, *Brugia malayi*, and *Loa loa*. - **Ineffective against intestinal nematodes** and can cause severe allergic reactions in filariasis patients.
Beta-Lactam Antibiotics
Practice Questions
Aminoglycosides
Practice Questions
Macrolides and Ketolides
Practice Questions
Tetracyclines
Practice Questions
Quinolones
Practice Questions
Sulfonamides and Trimethoprim
Practice Questions
Antimycobacterial Drugs
Practice Questions
Antifungal Agents
Practice Questions
Antiviral Drugs
Practice Questions
Antiparasitic Agents
Practice Questions
Principles of Antimicrobial Selection
Practice Questions
Antimicrobial Resistance
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free